Viridian Financial Statements From 2010 to 2024

Stocks . UK . 
Stock . Viridian Therapeutics
0K1R Stock   21.82  0.07  0.32%   
Viridian Therapeutics financial statements provide useful quarterly and yearly information to potential Viridian Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Viridian Therapeutics financial statements helps investors assess Viridian Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Viridian Therapeutics' valuation are summarized below:
Gross Profit
-99.1 M
Revenue
302 K
Earnings Share
(5.14)
Quarterly Revenue Growth
0.194
Revenue Per Share
0.005
There are over seventy-three available fundamental trend indicators for Viridian Therapeutics, which can be analyzed over time and compared to other ratios. All traders should double-check Viridian Therapeutics' current fundamentals against the performance from 2010 to 2024 and make sure the trends continue to evolve in the right direction.

Viridian Therapeutics Total Revenue

298,300

Check Viridian Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Viridian Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 391.8 K, Interest Expense of 1.9 M or Selling General Administrative of 99.7 M, as well as many indicators such as . Viridian financial statements analysis is a perfect complement when working with Viridian Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Viridian Therapeutics Technical models . Check out the analysis of Viridian Therapeutics Correlation against competitors.
For more information on how to buy Viridian Stock please use our How to Invest in Viridian Therapeutics guide.

Viridian Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets514.9 M490.4 M130.8 M
Slightly volatile
Short and Long Term Debt Total22.1 M21 M9.9 M
Pretty Stable
Other Current Liabilities24.4 M23.3 M7.2 M
Slightly volatile
Total Current Liabilities28 M26.6 M14.3 M
Pretty Stable
Property Plant And Equipment Net3.5 M3.3 M1.4 M
Slightly volatile
Current Deferred Revenue246.2 K259.2 K1.5 M
Very volatile
Accounts Payable2.1 M2.2 M1.7 M
Slightly volatile
Cash108 M102.8 M38.6 M
Slightly volatile
Non Current Assets Total2.5 M3.9 M2.2 M
Slightly volatile
Cash And Short Term Investments501.2 M477.4 M125.6 M
Slightly volatile
Net Receivables87.2 K91.8 K623.9 K
Slightly volatile
Common Stock Shares Outstanding47 M44.8 M9.8 M
Slightly volatile
Liabilities And Stockholders Equity514.9 M490.4 M130.8 M
Slightly volatile
Non Current Liabilities Total22.9 M21.8 M5.4 M
Slightly volatile
Other Current Assets9.5 M9 M3.2 M
Slightly volatile
Total Liabilities50.8 M48.4 M19.5 M
Slightly volatile
Total Current Assets510.8 M486.5 M128.6 M
Slightly volatile
Short Term Debt800.9 K843 K5.5 M
Slightly volatile
Common Stock567 K540 K196.5 K
Slightly volatile
Long Term Debt6.9 M5 M4.5 M
Slightly volatile
Capital Surpluse157.5 M250.8 M106.1 M
Slightly volatile
Property Plant Equipment3.5 M3.4 M1.3 M
Slightly volatile
Other Liabilities627.4 K1.1 M410.7 K
Slightly volatile
Short Term Investments393.3 M374.5 M102.9 M
Slightly volatile

Viridian Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization391.8 K522 K330.3 K
Slightly volatile
Interest Expense1.9 M1.8 M991.4 K
Pretty Stable
Selling General Administrative99.7 M95 M22.4 M
Slightly volatile
Selling And Marketing Expenses777.7 K800 K871.8 K
Slightly volatile
Total Revenue298.3 K314 K3.4 M
Slightly volatile
Other Operating Expenses267.5 M254.8 M64.4 M
Slightly volatile
Research Development167.8 M159.8 M40.1 M
Slightly volatile
Cost Of Revenue1.3 M1.3 M9 M
Pretty Stable
Total Operating Expenses267.5 M254.8 M63.1 M
Slightly volatile
Interest Income248.4 K385.2 K277 K
Very volatile

Viridian Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation70.5 M67.2 M13.3 M
Slightly volatile
Begin Period Cash Flow163.4 M155.6 M36.8 M
Slightly volatile
Depreciation548.1 K522 K244 K
Slightly volatile
Dividends Paid37.6 K39.6 K194.5 K
Slightly volatile
Capital Expenditures942.9 K898 K300.7 K
Slightly volatile
End Period Cash Flow108 M102.8 M38.6 M
Slightly volatile
Change To Netincome20.3 M22.8 M11.8 M
Slightly volatile

Viridian Fundamental Market Drivers

Cash And Short Term Investments477.4 M

About Viridian Therapeutics Financial Statements

Viridian Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Viridian Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Viridian Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Viridian Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue259.2 K246.2 K
Total Revenue314 K298.3 K
Cost Of Revenue1.3 M1.3 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
GOOGAlphabet Inc Class C
GOOGAlphabet Inc Class C

Additional Tools for Viridian Stock Analysis

When running Viridian Therapeutics' price analysis, check to measure Viridian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Viridian Therapeutics is operating at the current time. Most of Viridian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Viridian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Viridian Therapeutics' price. Additionally, you may evaluate how the addition of Viridian Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY